These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 12386036)

  • 1. Oral pristinamycin versus standard penicillin regimen to treat erysipelas in adults: randomised, non-inferiority, open trial.
    Bernard P; Chosidow O; Vaillant L;
    BMJ; 2002 Oct; 325(7369):864. PubMed ID: 12386036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cloxacillin versus pristinamycin for superficial pyodermas: a randomized, open-label, non-inferiority study.
    Chosidow O; Bernard P; Berbis P; Humbert P; Crickx B; Jarlier V;
    Dermatology; 2005; 210(4):370-4. PubMed ID: 15942235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pristinamycin in the treatment of acute bacterial dermohypodermitis in adults. An open study of 42 patients].
    Bernard P; Risse L; Bonnetblanc JM
    Ann Dermatol Venereol; 1996; 123(1):16-20. PubMed ID: 8734110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral versus intravenous antibiotics for bone and joint infections: the OVIVA non-inferiority RCT.
    Scarborough M; Li HK; Rombach I; Zambellas R; Walker AS; McNally M; Atkins B; Kümin M; Lipsky BA; Hughes H; Bose D; Warren S; Mack D; Folb J; Moore E; Jenkins N; Hopkins S; Seaton RA; Hemsley C; Sandoe J; Aggarwal I; Ellis S; Sutherland R; Geue C; McMeekin N; Scarborough C; Paul J; Cooke G; Bostock J; Khatamzas E; Wong N; Brent A; Lomas J; Matthews P; Wangrangsimakul T; Gundle R; Rogers M; Taylor A; Thwaites GE; Bejon P
    Health Technol Assess; 2019 Aug; 23(38):1-92. PubMed ID: 31373271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interventions for the prevention of recurrent erysipelas and cellulitis.
    Dalal A; Eskin-Schwartz M; Mimouni D; Ray S; Days W; Hodak E; Leibovici L; Paul M
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD009758. PubMed ID: 28631307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roxithromycin versus penicillin in the treatment of erysipelas in adults: a comparative study.
    Bernard P; Plantin P; Roger H; Sassolas B; Villaret E; Legrain V; Roujeau JC; Rezvani Y; Scheimberg A
    Br J Dermatol; 1992 Aug; 127(2):155-9. PubMed ID: 1390144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial.
    O'Riordan W; Cardenas C; Shin E; Sirbu A; Garrity-Ryan L; Das AF; Eckburg PB; Manley A; Steenbergen JN; Tzanis E; McGovern PC; Loh E;
    Lancet Infect Dis; 2019 Oct; 19(10):1080-1090. PubMed ID: 31474458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficiency of a four-day course of pristinamycin compared to a five-day course of cefuroxime axetil for acute bacterial maxillary sinusitis in adult outpatients].
    Gehanno P; Berche P; Hercot O; d'Arras L; Cabrillac-Rives S; Derobert E; Choné C
    Med Mal Infect; 2004 Jul; 34(7):293-302. PubMed ID: 15679233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A prospective study on erysipelas and infectious cellulitis: how are they dealt within hospital?].
    Schmit JL
    Ann Dermatol Venereol; 2001 Mar; 128(3 Pt 2):334-7. PubMed ID: 11319360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The course, costs and complications of oral versus intravenous penicillin therapy of erysipelas.
    Jorup-Rönström C; Britton S; Gavlevik A; Gunnarsson K; Redman AC
    Infection; 1984; 12(6):390-4. PubMed ID: 6394505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral pristinamycin for the treatment of resistant Gram-positive infections in patients with cancer: Evaluation of clinical outcomes.
    Teng JC; Lingaratnam SM; Trubiano JA; Thursky KA; Slavin MA; Worth LJ
    Int J Antimicrob Agents; 2016 May; 47(5):391-6. PubMed ID: 27089829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.
    Zhu HH; Wu DP; Du X; Zhang X; Liu L; Ma J; Shao ZH; Ren HY; Hu JD; Xu KL; Wang JW; Song YP; Fang MY; Li J; Yan XY; Huang XJ
    Lancet Oncol; 2018 Jul; 19(7):871-879. PubMed ID: 29884593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Penicillin V four times daily for five days versus three times daily for 10 days in patients with pharyngotonsillitis caused by group A streptococci: randomised controlled, open label, non-inferiority study.
    Skoog Ståhlgren G; Tyrstrup M; Edlund C; Giske CG; Mölstad S; Norman C; Rystedt K; Sundvall PD; Hedin K
    BMJ; 2019 Oct; 367():l5337. PubMed ID: 31585944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral linezolid compared with benzathine penicillin G for treatment of early syphilis in adults (Trep-AB Study) in Spain: a prospective, open-label, non-inferiority, randomised controlled trial.
    Ubals M; Nadal-Baron P; Arando M; Rivero Á; Mendoza A; Descalzo Jorro V; Ouchi D; Pérez-Mañá C; Álvarez M; Alemany A; Hoyos-Mallecot Y; Nunley E; Lieberman NAP; Greninger AL; Galván-Casas C; Suñer C; G-Beiras C; Paredes R; Rodríguez-Gascón A; Canut A; García-Patos V; Farré M; Marks M; Giacani L; Vall-Mayans M; Mitjà O
    Lancet Infect Dis; 2024 Apr; 24(4):404-416. PubMed ID: 38211601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Skin rash mimicking pityriasis rosea Gibert secondary to pristinamycin therapy].
    Schmutz JL; Trechot P
    Ann Dermatol Venereol; 2014 Apr; 141(4):325-6. PubMed ID: 24703654
    [No Abstract]   [Full Text] [Related]  

  • 16. Successful oral pristinamycin therapy for osteoarticular infections due to methicillin-resistant Staphylococcus aureus (MRSA) and other Staphylococcus spp.
    Ng J; Gosbell IB
    J Antimicrob Chemother; 2005 Jun; 55(6):1008-12. PubMed ID: 15845784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amoxicillin duration and dose for community-acquired pneumonia in children: the CAP-IT factorial non-inferiority RCT.
    Barratt S; Bielicki JA; Dunn D; Faust SN; Finn A; Harper L; Jackson P; Lyttle MD; Powell CV; Rogers L; Roland D; Stöhr W; Sturgeon K; Vitale E; Wan M; Gibb DM; Sharland M
    Health Technol Assess; 2021 Nov; 25(60):1-72. PubMed ID: 34738518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
    Portsmouth S; van Veenhuyzen D; Echols R; Machida M; Ferreira JCA; Ariyasu M; Tenke P; Nagata TD
    Lancet Infect Dis; 2018 Dec; 18(12):1319-1328. PubMed ID: 30509675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intramuscular bipenicillin vs. intravenous penicillin in the treatment of erysipelas in adults: randomized controlled study.
    Zeglaoui F; Dziri C; Mokhtar I; Ezzine N; Kharfi M; Zghal M; Fazaa B; Kamoun MR
    J Eur Acad Dermatol Venereol; 2004 Jul; 18(4):426-8. PubMed ID: 15196155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT.
    Iveson T; Boyd KA; Kerr RS; Robles-Zurita J; Saunders MP; Briggs AH; Cassidy J; Hollander NH; Tabernero J; Haydon A; Glimelius B; Harkin A; Allan K; McQueen J; Pearson S; Waterston A; Medley L; Wilson C; Ellis R; Essapen S; Dhadda AS; Harrison M; Falk S; Raouf S; Rees C; Olesen RK; Propper D; Bridgewater J; Azzabi A; Farrugia D; Webb A; Cunningham D; Hickish T; Weaver A; Gollins S; Wasan H; Paul J
    Health Technol Assess; 2019 Dec; 23(64):1-88. PubMed ID: 31852579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.